Skip to main content

Price-sensitive press releases

2021-10-22
STOCKHOLM, October 22[nd], 2021 – In accordance with the resolution of the Annual General Meeting on May 18[th], 2021, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 18[th], 2021.
2021-09-22
Moberg Pharma AB (OMX: MOB) today announces that it has received approval of the pediatric plan for MOB-015 from EMA’s paediatric committee (PDCO). This approval enables the company to pursue a full marketing authorization application providing up to ten years of exclusivity in Europe following approval. The company´s timeline remains, with planned submission for MOB-015 in Europe this year and expected market approval in 2023.
2021-08-10
REGISTRATION PREPARATIONS FULLY UNDERWAY
2021-07-30
STOCKHOLM, July 30[th], 2021, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 45,511,425. The 910,000 newly issued shares are held by the company to secure its commitments under incentive programmes.
2021-06-23
STOCKHOLM, June 23[th], 2021, Moberg Pharma AB (OMX: MOB) announces the appointment of Agneta Larhed as Vice President Pharmaceutical Innovation & Development of Moberg Pharma. Dr Larhed will be joining the management team at Moberg Pharma in September.
2021-05-18
STOCKHOLM, May 18[th], 2021. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.
2021-05-11
REGISTRATION PREPARATIONS FULLY UNDERWAY 
2021-04-19
Shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company”) are hereby convened to the Annual General Meeting on Tuesday, 18 May 2021.
2021-02-09
Financing for both MOB-015 and BUPI
2021-02-02
STOCKHOLM, February 2[nd], 2021 - On February 9[th], 2021, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Year-end report for the financial year 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.